Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
Moodys
Johnson and Johnson
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Canakinumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Canakinumab: Sponsors, patents, clinical trial progress

Canakinumab is an investigational drug.

There have been 68 clinical trials for Canakinumab. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2014.

The most common disease conditions in clinical trials are Arthritis, Syndrome, and Arthritis, Juvenile. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and Charite University, Berlin, Germany.

There are twenty-two US patents protecting this investigational drug and three hundred and fifty-eight international patents.

Recent Clinical Trials for Canakinumab
TitleSponsorPhase
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.Novartis PharmaceuticalsPhase 2
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaNovartisEarly Phase 1
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaCharles G. DrakeEarly Phase 1

See all Canakinumab clinical trials

Clinical Trial Summary for Canakinumab

Top disease conditions for Canakinumab
Top clinical trial sponsors for Canakinumab

See all Canakinumab clinical trials

US Patents for Canakinumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Canakinumab   Start Trial Use of IL-1 .beta. binding antibodies for treating peripheral arterial disease Novartis AG (Basel, CH)   Start Trial
Canakinumab   Start Trial Trilayer coated pharmaceutical packaging SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)   Start Trial
Canakinumab   Start Trial Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody The Children's Hospital of Philadelphia (Philadelphia, PA) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
Canakinumab   Start Trial Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development TRUSTEES OF BOSTON UNIVERSITY (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Canakinumab

Drugname Country Document Number Estimated Expiration Related US Patent
Canakinumab Australia 2013344796 2032-11-16   Start Trial
Canakinumab Canada 2891556 2032-11-16   Start Trial
Canakinumab European Patent Office 2919811 2032-11-16   Start Trial
Canakinumab Japan 2016502526 2032-11-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
AstraZeneca
Johnson and Johnson
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.